Literature DB >> 16242838

Oncogenic rearrangements of the NTRK1/NGF receptor.

Marco A Pierotti1, Angela Greco.   

Abstract

The NTRK1 gene encodes the high affinity receptor for Nerve Growth Factor, and its action regulates neural development and differentiation. Deregulation of NTRK1 activity is associated with several human disorders. Loss of function mutations causes the genetic disease congenital insensitivity to pain with anhidrosis (CIPA). Constitutive activation of NTRK1 has been detected in several tumor types. An autocrine loop involving NTRK1 and NGF is associated with tumor progression in prostate carcinoma and in breast cancer. A novel alternative splicing variant with constitutive oncogenic potential has been recently described in neuroblastoma. Somatic rearrangements of NTRK1, producing chimeric oncogenes with constitutive tyrosine kinase activity, have been detected in a consistent fraction of papillary thyroid tumors. The topic of this review is a detailed analysis of the thyroid TRK oncogenes. The modalities of their activation, their mechanism of action, the contribution of activating sequences, and the molecular mechanisms underlying their generation will be discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16242838     DOI: 10.1016/j.canlet.2005.07.043

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  26 in total

1.  Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies.

Authors:  Glen J Weiss; Manuel Hidalgo; Mitesh J Borad; Daniel Laheru; Raoul Tibes; Ramesh K Ramanathan; Lisa Blaydorn; Gayle Jameson; Antonio Jimeno; Jeffrey D Isaacs; Angela Scaburri; Maria Adele Pacciarini; Francesco Fiorentini; Marina Ciomei; Daniel D Von Hoff
Journal:  Invest New Drugs       Date:  2011-12-09       Impact factor: 3.850

2.  AZ64 inhibits TrkB and enhances the efficacy of chemotherapy and local radiation in neuroblastoma xenografts.

Authors:  Radhika Iyer; Carly R Varela; Jane E Minturn; Ruth Ho; Anisha M Simpson; Jennifer E Light; Audrey E Evans; Huaqing Zhao; Kenneth Thress; Jeffrey L Brown; Garrett M Brodeur
Journal:  Cancer Chemother Pharmacol       Date:  2012-05-24       Impact factor: 3.333

Review 3.  On Trk--the TrkB signal transduction pathway is an increasingly important target in cancer biology.

Authors:  Carol J Thiele; Zhijie Li; Amy E McKee
Journal:  Clin Cancer Res       Date:  2009-09-15       Impact factor: 12.531

4.  (R)-2-Phenylpyrrolidine Substituted Imidazopyridazines: A New Class of Potent and Selective Pan-TRK Inhibitors.

Authors:  Ha-Soon Choi; Paul V Rucker; Zhicheng Wang; Yi Fan; Pamela Albaugh; Greg Chopiuk; Francois Gessier; Fangxian Sun; Francisco Adrian; Guoxun Liu; Tami Hood; Nanxin Li; Yong Jia; Jianwei Che; Susan McCormack; Allen Li; Jie Li; Auzon Steffy; AnneMarie Culazzo; Celine Tompkins; Van Phung; Andreas Kreusch; Min Lu; Bin Hu; Apurva Chaudhary; Mahavir Prashad; Tove Tuntland; Bo Liu; Jennifer Harris; H Martin Seidel; Jon Loren; Valentina Molteni
Journal:  ACS Med Chem Lett       Date:  2015-03-16       Impact factor: 4.345

5.  Lidocaine treatment during synapse reformation periods permanently inhibits NGF-induced excitation in an identified reconstructed synapse of Lymnaea stagnalis.

Authors:  Shin Onizuka; Seiji Shiraishi; Ryuuji Tamura; Tetsu Yonaha; Nobuko Oda; Yuko Kawasaki; Naweed I Syed; Tetsuro Shirasaka; Isao Tsuneyoshi
Journal:  J Anesth       Date:  2011-10-30       Impact factor: 2.078

Review 6.  Aiding and abetting cancer: mRNA export and the nuclear pore.

Authors:  Biljana Culjkovic-Kraljacic; Katherine L B Borden
Journal:  Trends Cell Biol       Date:  2013-04-10       Impact factor: 20.808

7.  A novel HSP90 modulator with selective activity against thyroid cancers in vitro.

Authors:  Abbas Samadi; Peter Loo; Rithwi Mukerji; Gemma O'Donnell; Xiaqin Tong; Barbara N Timmermann; Mark S Cohen
Journal:  Surgery       Date:  2009-12       Impact factor: 3.982

8.  Genetic Predisposition to Familial Nonmedullary Thyroid Cancer: An Update of Molecular Findings and State-of-the-Art Studies.

Authors:  Elena Bonora; Giovanni Tallini; Giovanni Romeo
Journal:  J Oncol       Date:  2010-06-10       Impact factor: 4.375

Review 9.  Nuclear pore proteins and cancer.

Authors:  Songli Xu; Maureen A Powers
Journal:  Semin Cell Dev Biol       Date:  2009-03-18       Impact factor: 7.727

10.  Gene expression profiling associated with the progression to poorly differentiated thyroid carcinomas.

Authors:  J M Pita; A Banito; B M Cavaco; V Leite
Journal:  Br J Cancer       Date:  2009-10-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.